All In Biotech

Drug Trial Radar · NCT07542158

Ultralow Dose PET Imaging of 18F-FDOPA

Evaluation of Ultralow Dose PET Imaging for Detecting 18F-FDOPA Uptake

Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

200

Planned (sponsor's estimate)

Start

May 12, 2025

Primary completion

Jun 30, 2030

Study completion Jun 30, 2030

Sponsor

Lead sponsor
Akiva MintzAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 120 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for Parkinsonian syndromes, neuroendocrine tumors, and gliomas detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-FDOPA and be imaged on a new type of high sensitivity PET scanner for up to 3 hours.

Conditions

  • Heathy Volunteer
  • Parkinsonian Syndromes
  • Neuroendocrine (NE) Tumors
  • Gliomas

Interventions

  • 18F-FDOPADrug

    Participants will be injected with 18F-FDOPA and imaged for up to 3 hours on a PET scanner

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Signal-to-Noise Ratio (SNR)Time frame: Single timepoint (Day 1, imaging visit); aggregated analysis conducted annually using data from the prior 12 months, through study completion (up to 5 years).
  2. Contrast-to-Noise Ratio (CNR)Time frame: Single timepoint (Day 1, imaging visit); aggregated analysis conducted annually using data from the prior 12 months, through study completion (up to 5 years).
  3. Coefficient of Variation (COV)Time frame: Single timepoint (Day 1, imaging visit); aggregated analysis conducted annually using data from the prior 12 months, through study completion (up to 5 years).
  4. Spatial Resolution (Full Width at Half Maximum - FWHM)Time frame: Single timepoint (Day 1, imaging visit); aggregated analysis conducted annually using data from the prior 12 months, through study completion (up to 5 years).
  5. Target-to-Background Ratio (TBR)Time frame: Single timepoint (Day 1, imaging visit); aggregated analysis conducted annually using data from the prior 12 months, through study completion (up to 5 years).
  6. Qualitative Image Quality Score (Likert Scale)Time frame: Single timepoint (Day 1, imaging visit); aggregated analysis conducted annually using data from the prior 12 months, through study completion (up to 5 years).
  7. Inter-reader Agreement (Weighted Kappa Statistics)Time frame: Single timepoint (Day 1, imaging visit); aggregated analysis conducted annually using data from the prior 12 months, through study completion (up to 5 years).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nuclear Imaging Institute

    Englewood, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.